Skip to main content

Table 1 Baseline Patient Characteristics

From: A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)

Characteristics

HLA-A*2402

p value

Matched (n = 50)

Unmatched (n = 46)

Sex

    
 

Male

25

24

NS

 

Female

25

22

 

Age

    
 

Mean

64.3

63.4

NS

 

Standard error

10.9

8

 
 

Range

36-82

38-77

 

Unresectable site

   
 

Liver

27

35

 
 

Lung

18

12

 
 

Dissemination

5

4

NS

 

Bone

1

2

 
 

Lymphnode

13

13

 
 

Other

5

1

 

Number of unresectable sites

   
 

1

36

30

 
 

2

9

11

 
 

3

5

5

 

Resection of primary lesion

   
 

yes

41

43

 
 

no

9

3

NS

Chemotherapy

   
 

FOLFOX

48

45

 
 

XELOX

2

1

NS

 

(Bevacizumab)

0

(5)

 

Primary minor site

   
 

Colon

29

36

0.057

 

Rectal

21

10

 
  1. FOLFOX. infusional fluorouracil. leucovorin. and oxaliplatin: XELOX. capecitabine and oxaliplatin; HLA, human leukocyte antigen; NS. not significant.